IP Library › Granted Patent US 7,498,137
Granted Patent B2
US 7,498,137 · App. 11/448,531 · Granted Mar 3, 2009

Compositions and methods for determining the presence of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,498,137
App. No.
11/448,531
Granted
Mar 3, 2009
Kind
B2
Abstract

The present invention relates to oligonucleotides useful for determining the presence of Chlamydophila pneumoniae in a test sample. The oligonucleotides of the present invention may be incorporated into detection probes, capture probes and amplification oligonucleotides, and used in various combinations thereof.

Claims (30)

1. A detection probe for use in determining the presence of Chlamydophila pneumoniae in a test sample, said probe being up to 50 bases in length and comprising a target binding region that forms a probe:target hybrid stable for detection with a target sequence contained within a target region selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4 under stringent hybridization conditions, wherein said target binding region comprises the nucleotide base sequence of SEQ ID NO:5, SEQ ID NO: 6, SEQ ID NO:7, or SEQ ID NO:8, and wherein said probe does not form a hybrid stable for detection with nucleic acid derived from Chlamydia trachomatis or Chlamydophila psittaci under said conditions.

2. The detection probe of claim 1 , wherein said probe is up to 40 bases in length.

3. The detection probe of claim 1 , wherein said probe is up to 35 bases in length.

4. The detection probe of claim 1 , wherein said probe is up to 30 bases in length.

5. The detection probe of claim 1 , wherein said probe is up to 25 bases in length.

6. The detection probe of claim 1 , wherein said probe is up to 20 bases in length.

7. The detection probe of claim 1 , wherein said probe fully hybridizes to said target region.

8. The detection probe of claim 7 , wherein said target binding region consists of the base sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.

9. The detection probe of claim 1 , wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.

10. The detection probe of claim 1 , wherein said probe includes a detectable label.

11. The detection probe of claim 1 , wherein said probe is a self-hybridizing probe under said conditions and in the absence of said target sequence.

12. The detection probe of claim 1 , wherein said probe comprises a pair of interacting labels.

13. The detection probe of claim 1 , wherein said target binding region includes at least one 2′-O-methyl ribonucleotide.

14. The detection probe of claim 1 , wherein said conditions include a temperature of about 60° C. and a salt concentration of about 0.6 M to about 0.9 M.

15. A composition comprising said probe of claim 1 hybridized to nucleic acid derived from Chlamydophila pneumoniae under said conditions.

16. A method for determining the presence of Chlamydophila pneumoniae in a test sample, said method comprising the steps of:

(a) contacting a test sample with said probe of claim 1 under said conditions; and

(b) determining whether said probe:target hybrid is present in said test sample as indication of the presence of Chlamydophila pneumoniae in said test sample.

17. The method of claim 16 , wherein said probe is up to 40 bases in length.

18. The method of claim 16 , wherein said probe is up to 35 bases in length.

19. The method of claim 16 , wherein said probe is up to 30 bases in length.

20. The method of claim 16 , wherein said probe is up to 25 bases in length.

21. The method of claim 16 , wherein said probe is up to 20 bases in length.

22. The method of claim 16 , wherein said probe fully hybridizes to said target region.

23. The method of claim 22 , wherein said target binding region consists of the base sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.

24. The method of claim 16 , wherein the base sequence of said probe consists of the base sequence of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or SEQ ID NO:8.

25. The method of claim 16 , wherein said probe includes a detectable label.

26. The method of claim 16 , wherein said probe is a self-hybridizing probe under said conditions and in the absence of said target sequence.

27. The method of claim 26 , wherein said probe comprises a pair of interacting labels.

28. The method of claim 16 , wherein said target binding region includes at least one 2′-O-methyl ribonucleotide.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →